Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Abbot, abuse, accreted, ACE, ACEON, ADAPT, affirmative, Aldosterone, allosteric, allosterically, alter, American, amlodipine, Anergen, angiotensin, Annex, annum, antihypertensive, appendix, ARB, arginine, Aryx, asthma, BA, Baker, baseline, bellwether, besylate, Biofarma, biophysical, Bioscience, Blair, branded, breast, Brovana, calcium, cancel, cancellation, category, CDR, channel, charter, cholesterol, Circuit, colchicine, condensed, coordinated, coronary, CRP, cure, Daiichi, damage, Davidson, defraud, Demurrer, device, DGCL, diastolic, differential, diligent, Diovan, dismissed, distinct, diuretic, Eastern, Elan, elevated, Endocrinology, endpoint, enzyme, epidermal, erbumine, erosive, exert, expenditure, eye, false, FDC, Felix, FEOMA, ficlatuzumab, follicular, Funxional, Futhermore, GECC, gefitinib, genericized, Genset, gevokizumab, glycemic, gouty, guarantor, Guerrero, Harwell, HDL, Hematologic, hematological, HFA, HHSN, Hilditch, HIPAA, HITECH, homeostatic, hormone, hypertension, IgG, Immunology, imprisonment, inappropriate, incorrect, inhibitor, insolvency, insulin, intermediate, Introduction, Julian, knowingly, Krawiec, lipoprotein, lisinopril, longest, Lotrel, LP, lucatumumab, Lunesta, LUVENIQ, Lux, mandatory, marker, Marsh, Medicaid, Medicare, Medpace, merging, metabolic, metastatic, mice, Michigan, moderate, ModulX, mouse, Muniz, mutant, mycophenalate, Myfortic, NDA, Neurex, NIU, noncompliance, nonowner, Occidental, Onondaga, ophthalmic, OptimX, OrbiMed, organizational, Ortiz, Parent, PATH, Paul, perindopril, Pharmacology, pharmacovigilance, Physician, play, Portability, posterior, postpone, prejudice, Prinivil, privacy, prolactin, prominence, prominent, prostate, qui, rapamycin, reactive, recalled, recover, referral, reformatting, refractory, relief, relinquish, remedy, remuneration, Renin, reproduce, resistance, Resolvyx, retirement, Royal, RSU, Rubin, Rush, salt, Sankyo, Santen, scheme, secondarily, secondary, Sepracor, seventy, sharpen, sitting, sodium, soliciting, solid, spot, statute, stockholder, streamlining, stroke, succeeding, Sunshine, Supreme, surrender, Sylvia, systolic, tam, Tarka, telecommunication, tenure, terrorism, Teva, Tifenthal, transmission, triple, unannounced, unregistered, valsartan, Varian, voclosporin, war, warehouse, Western, White, willingly, Wisconsin, XMet, XMetA, Xopenex, yeast, ZESTRIL, zilueton
Removed:
AB, accrual, affiliate, Alexion, augment, Avecia, bankruptcy, batch, biomedical, Bioshield, biotech, book, bring, career, Chapter, chose, Continuance, contrary, Dealer, decided, delisted, depending, designated, dilute, disclosed, domicile, EMEA, enforcement, entertain, eradication, exchanged, extending, extreme, FASB, Force, formalized, fragment, fulfillment, gastrointestinal, gel, Genome, globulin, herewith, history, impetigo, inconclusive, increasing, installment, introduced, irrevocably, irritation, Jolla, La, lab, leadership, Memorandum, Micro, nation, netted, overnight, peptide, perpetual, PharmAthene, plant, predecessor, predicated, prejudicial, rank, ratio, reevaluate, refinancing, reformulate, reformulated, reorganization, resulted, revised, skin, slightly, SNAPsSM, spend, spent, Stanford, suited, superficial, Taligen, Task, temporarily, topical, treaty, typical, unamortized, unproven, unutilized, update, utilization, vehicle
Filing tables
Filing exhibits
- 10-K Annual report
- 4.9 Exhibit 4.9
- 10.6 Exhibit 10.6A
- 10.6 Exhibit 10.6B
- 10.7 Exhibit 10.7B
- 10.10 Exhibit 10.10G
- 10.12 Exhibit 10.12A
- 10.25 Exhibit 10.25B
- 10.41 Exhibit 10.41A
- 10.43 Exhibit 10.43
- 10.43 Exhibit 10.43A
- 10.44 Exhibit 10.44
- 10.44 Exhibit 10.44A
- 10.45 Exhibit 10.45
- 10.45 Exhibit 10.45A
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- 32.2 Exhibit 32.2
- 99.1 Exhibit 99.1
XOMA similar filings
Filing view
External links
EXHIBIT 10.7B
AMENDMENT NO. 1 TO THE XOMA LTD.
CEO INCENTIVE COMPENSATION PLAN
The XOMA Ltd. CEO Incentive Compensation Plan (the “Plan”) is hereby amended, effective as of October 27, 2011, by amending Sections 2(a) and 2(b) of the Plan to read in their entirety as follows:
“(a) It is the intention of the Board that awards to the CEO share vary depending on: (1) the extent of achievement of Company Objectives; (2) the CEO’s Base Salary; (3) the CEO’s performance based on the criteria set forth in the Company’s CEO evaluation form; and (4) the CEO’s achievement of certain individual performance objectives to be determined from time to time by the Board in its sole discretion.
“(b) Company and individual performance goals for the CEO are to be weighted as follows:
Company Objectives | CEO Evaluation Form Criteria | Individual Performance Objectives |
50% | 30% | 20%” |